EC grants conditional approval to daratumumab in multiple myeloma
The European Commission (EC) has granted conditional approval to Janssen’s Darzalex (daratumumab) for monotherapy of adult patients with relapsed and refractory multiple myeloma (MM), whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.
Click on this link for more information.
